Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clomiphene
Drug ID BADD_D00497
Description A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Indications and Usage Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome) to induce ovulation.
Marketing Status approved; investigational
ATC Code G03GB02
DrugBank ID DB00882
KEGG ID D07726
MeSH ID D002996
PubChem ID 1548953
TTD Drug ID D0CT9Y
NDC Product Code Not Available
UNII 1HRS458QU2
Synonyms Clomiphene | Clomifene | Chloramiphene | Clomifen | Clomiphene Citrate | Citrate, Clomiphene | Clomiphene Hydrochloride | Hydrochloride, Clomiphene | Serophene | Gravosan | Klostilbegit | Clostilbegit | Clomid | Clomide | Dyneric
Chemical Information
Molecular Formula C26H28ClNO
CAS Registry Number 15690-57-0
SMILES CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thyroid disorder05.02.01.002--Not Available
Thyroid neoplasm16.24.01.002; 05.02.05.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue neoplasm malignant stage unspecified07.21.07.003; 16.13.07.003--Not Available
Tracheo-oesophageal fistula22.04.07.003; 07.11.05.003; 03.16.02.002--Not Available
Trisomy 2119.21.06.005; 17.03.07.005; 02.08.02.003; 03.20.01.002--Not Available
Umbilical hernia07.16.03.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Vasospasm24.04.02.002--Not Available
Ventricular septal defect02.04.02.007; 03.07.02.001--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual acuity reduced06.02.10.012; 17.17.01.011--
Visual field defect06.02.07.003; 17.17.01.001--Not Available
Visual impairment06.02.10.013--Not Available
Vitreous detachment12.01.04.005; 06.09.01.002--Not Available
Vitreous floaters06.09.01.005--
Vomiting07.01.07.003--
Vulvovaginal dryness21.08.02.003--
Weight increased13.15.01.006--
Hydrothorax22.05.02.004--Not Available
Breast discomfort21.05.05.007--Not Available
Neural tube defect17.19.02.002; 03.10.02.003--Not Available
Foetor hepaticus07.01.06.026; 09.01.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Transaminases increased13.03.04.036--Not Available
Neuroectodermal neoplasm16.30.01.006; 17.20.01.006--Not Available
Adnexa uteri pain21.07.04.006--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages